All News
Filter News
Found 77 articles
-
Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients
10/23/2018
Over Half of Patients Treated with Tanezumab Reported a 50 Percent or Greater Reduction in Osteoarthritis Pain of the Knee or Hip
-
Regeneron and Teva’s Fasinumab Hits Primary and Secondary Endpoints in Late-Stage Sub Study
8/16/2018
Regeneron’s fasinumab hit the mark in a late-stage study assessing patients with chronic pain from osteoarthritis (OA) of the knee or hip. At 16 weeks patients experienced significantly less pain and also showed significantly improved functional ability from baseline. -
PFIZER REPORTS SECOND-QUARTER 2018 RESULTS
7/31/2018
Second-Quarter 2018 Revenues of $13.5 Billion, Reflecting 2% Operational Growth
-
Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance
7/24/2018
Second-quarter 2018 revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products, while operating expenses declined.
-
Pfizer and Eli Lilly released results from its 16-week Phase III clinical trial in patients with osteoarthritis (OA) pain receiving a subcutaneous dose of tanezumab. The drug hit all three co-primary endpoints.
-
Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
7/18/2018
Tanezumab is also being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
-
Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache
6/25/2018
American Headache Society (AHS) annual meeting is taking place June 28-July 1 in San Francisco.
-
BioSpace takes a look at some notable programs that have been shuttered so far this year.
-
Safety Concerns Force Regeneron to Halt High Doses of NGF-Inhibitor Fasinumab in Phase III Trial
5/3/2018
Regeneron has halted high dose treatment of a Phase III osteoarthritis drug following a risk-benefit assessment conducted by an Independent Data Monitoring Committee. -
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
-
Pfizer Reports Fourth-Quarter And Full-Year 2017 Results
1/30/2018
Full-year 2017 revenues totaled $52.5 billion, a decrease of $278 million, or 1%, reflecting a slight operational decline of $20 million, or less than 1%, and the unfavorable impact of foreign exchange of $259 million, or less than 1%.
-
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference.
-
About 200 of the job cuts will be in Massachusetts, the remaining in Connecticut.
-
FDA Accepts BLA to Review Eli Lilly's Galcanezumab for the Prevention of Migraine in Adults
12/11/2017
Lilly announced the submission of the BLA on its third-quarter earnings call in October 2017.
-
Levicept Starts First-In-Human Phase I Trial Of LEVI-04, A Novel Fusion Protein Therapy For Chronic Pain
9/15/2017
-
Eli Lilly Chops 3,500 Jobs, Shuts Down 2 R&D Sites
9/11/2017
-
Eli Lilly Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs
7/26/2017
-
Pfizer And Eli Lilly Receive FDA Fast Track Designation For Tanezumab
6/13/2017
-
Massachusetts' CoLucid Pharma Surges on $960 Million Eli Lilly Buyout Deal
1/19/2017
-
FDA Slaps Hold on Regeneron, Teva's Pain Drug Fasinumab
10/18/2016